ARTICLE | Clinical News
OXi4503 combretastatin A1 di-phosphate: Phase Ib/II started
November 2, 2015 8:00 AM UTC
OxiGene began an open-label, U.S. Phase Ib/II trial to evaluate OXi4503 as a single agent and in combination with intermediate-dose cytarabine. The dose-escalation Phase Ib portion will enroll up to 2...